

## Special Issue

# Hematological Malignancy: From Pathophysiology to Novel Therapeutic Approaches

### Message from the Guest Editors

Despite advances in the understanding of hematological malignancies' pathophysiology, the treatment of hematological neoplasms remains challenging. Improving the therapeutic efficacy of existing therapies or developing a novel therapeutic agent is urgently needed. This Special Issue of *Biomedicines*, titled "Hematological Malignancy: From Pathophysiology to Novel Therapeutic Approaches" will include reviews that describe novel strategies for treating hematological malignancies developed over the past few years as well as original research articles that describe novel discoveries in the pathophysiology of hematological neoplasms and strategies for treating hematological malignancies using preclinical and/or translational studies. In addition, studies on biomarkers, combination therapy, drug responses, the tumor microenvironment, and mechanistic approaches will be accepted.

### Guest Editors

Prof. Dr. Jacek Tabarkiewicz

Department of Human Immunology, College of Medical Science,  
Institute of Medicine, University of Rzeszów, Rzeszów, Poland

Dr. Norbert Grząśko

Department of Experimental Hematooncology, Medical University of  
Lublin, Lublin, Poland; Department of Hematology, Center of Oncology  
of the Lublin Region St. Jana z Dukli, Lublin, Poland

### Deadline for manuscript submissions

closed (31 July 2021)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/77703](https://mdpi.com/si/77703)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).